Experts are rapidly focused on retatrutide, a innovative drug developed by Eli Lilly, as a significant step in physique loss . Unlike many existing approaches, retatrutide is a dual -action agonist targeting equally GLP-1 and GIP, substances that impact hunger and blood glucose control . Initial